Andrew Currier

Andrew is a recognized leader in intellectual property combining experience in industry, law and academia before co-founding PCK, one of Canada’s leading IP firms. Andrew is a registered patent agent in both Canada and the US with industry experience from start-ups in Silicon Valley to publicly traded companies. Andrew holds an appointment as Adjunct Professor at the University of Windsor Faculty of Law and previously held a teaching appointment as Adjunct Professor at Western Law School in London Ontario teaching patent law. Cited by the Supreme Court of Canada, he is also co-author (with Stephen Perry) of Canadian Patent Law (2nd ed. Butterworths, 2014) the first text on Canadian patent law by practitioners in over thirty years.

Andrew’s breadth of expertise is demonstrated through his practice where he counsels clients on all aspects of intellectual property. This includes strategy, invention mining, branding, portfolio management, commercialization, litigation and dispute resolution, built on a core foundation of excellence in originating patent and trademark preparation, filing and prosecution. His clients span the range of start-ups to large enterprises, and he takes pride in bringing his skills to the corporate journey all the way from founding to scaling and maturity.

He has worked on a variety of significant transactions in healthcare and life sciences including acting on behalf of Excedrin in a major litigation between Excedrin and McNeil Consumer Healthcare, a subsidiary of Johnson & Johnson. Andrew has also represented several large organizations within the sector including Teva, UHN and Cook.